|Salary:||£32,236 to £39,609 p.a. (Grade 7)|
|Placed On:||20th August 2019|
|Closes:||30th September 2019|
We are seeking an ambitious and highly motivated postdoctoral scientist to lead a programme of research that aims to investigate a new drug target in alpha-synuclein pathobiology. The study will involve the use of biochemical approaches, including proteomics, CRISPR/Cas9 modulation of USP8 in iPSC-based models and the characterisation of small molecules.
The post will offer an excellent opportunity for mechanistic research and drug development in Parkinson’s disease using state-of-the-art models and facilities at the Nuffield Department of Clinical Neurosciences of the University of Oxford. The postholder with also benefit from and be exposed to interactions with industry and work alongside a multidisciplinary team in the Molecular Neurodegeneration Research Group (www.ndcn.ox.ac.uk/research/molecular-neurodegeneration-research-group).
The postholder will be expected to manager their own academic research and take initiative, alongside developing new assays and using established lab protocols to differentiate iPSC into neurons. They will also be responsible for performing experiments involving proteomics and confocal microscopy and generating new constructs relevant to the project using CRISPR.
The successful candidate should hold a PhD or equivalent degree and have proven track record in molecular biology including cloning of constructs and use of lentiviruses. Alongside this the postholder must have experience in cell culture, ideally of iPSC-derived neurons and an aptitude for mechanistic studies using proteomic and molecular techniques. It is essential that they have an understanding of molecular mechanisms of ubiquitin signalling or proteostasis, and the enthusiasm to lead a project as well as the ability to work collaboratively within a team.
It would be beneficial if the postholder also had knowledge in ubiquitin biology and/or proteostasis and if they had experience in supervising junior researchers.
Recent publication relating to this programme of research: Alexopoulou et al., PNAS 2016; 113(32):E4688-97. Tofaris et al., PNAS 2011; 108(41):17004-9.
Informal enquiries are encouraged and should be addressed to Dr George Tofaris: email@example.com>
The post is full-time for a fixed-term of 1 year in the first instance.
Only applications received before 12.00 midday on 30 September 2019 will be considered. Interviews will be held as soon as possible thereafter.
Closing Date: 30-SEP-2019 12:00
Type / Role: